TTK Healthcare Limited
Valuation (93/100) does the heavy lifting; quality (53/100) is the drag.
Buy zoneStocksWizard rates TTK Healthcare Limited a Strong Buy, scoring 78/100 on our blended model. On 22.5x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 6% below its 52-week high of ₹1,191 and 52% above the low of ₹732.12. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9. It clears 9 of 13 investability checks, with durability 53, valuation 86 and momentum 92 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,606.67.
1-year price
EOD · 2026-09-1452-week range
-6.35% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy78Piotroski F-score 1/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 6.0%
- Pass: Low debt (D/E < 0.5): 0.02x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 14%
- Pass: Earnings growing: 35%
- Fail: Net margin ≥ 10%: 7.7%
- Pass: Current ratio > 1.5: 5.91
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.51
- Fail: Piotroski ≥ 7: 1/9
Shareholding
- Promoter75.6%
- Institutions1.9%
- Public & other22.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 6.51.
Opportunities
- Earnings growing (35% YoY).
- Revenue growing (14% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~80% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (6.0%).
- Weak Piotroski score (1/9).
About TTK Healthcare Limited
TTK Healthcare Limited operates across animal welfare, consumer products, medical devices, protective devices, and foods in India. Its Animal Welfare segment produces feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, and cocktail enzymes. The company also maintains Consumer Products, Medical Devices, Foods, Protective Devices, and Other business segments.
TTK Healthcare Limited — frequently asked questions
Is TTK Healthcare Limited a buy, hold or sell?
StocksWizard currently rates TTK Healthcare Limited (TTKHLTCARE) a Strong Buy, based on a blended score of 78/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is TTK Healthcare Limited's fair value?
Our blended DCF and relative-valuation model estimates TTK Healthcare Limited's fair value at about ₹2,008.34, versus a current price of ₹1,115.4 — roughly 80% upside. On that basis the stock looks undervalued by 80%.
Is TTK Healthcare Limited financially healthy?
TTK Healthcare Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9.
How has TTK Healthcare Limited's share price performed?
TTK Healthcare Limited is up 28% over three months, and last traded at ₹1,115.4. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.